We assessed somatic MB in surgical tumor specimens with whole exome sequencing (WES) using an ion torrent proton platform (Thermo Fisher Scientific). Two hundred forty-six NSCLC patients were randomly divided into training (n ¼ 123) and validation (n ¼ 123) cohorts. We defined patients with a greater than median number of non-synonymous (n-syn) mutations as the higher MB group. To detect higher n-syn MB in the training cohort, clinical data was assessed using a stepwise regression model. The validation cohort was subsequently analyzed. Also, the detected factors were validated via 100 repetitions of this procedure with different randomly divided cohorts using bootstrapping method. Background: PD-L1 expression is associated with clinical benefit from anti-PD1/anti-PD-L1 therapies in advanced NSCLC. However, additional biomarkers are needed to predict which patients will benefit most. The aim of this study is to correlate specific genomic alterations with immunological biomarkers in a cohort of NSCLC. Methods: Patients diagnosed with NSCLC from 2000 to 2005 were retrospectively reviewed. Genetic mutations and copy number of selected genes were determined by Sanger and FISH. Immunophenotype was defined by PD-L1, HLA-1 and TILs CD8þ immunostaining and scored as follows: PD-L1 positivity 5% on membrane tumor cells; HLA-1 intensity: 0þ,1þ,2þ; TILs CD8þ score: low or high infiltration. Statistical analysis using Chi-square test and logistic regression were performed. Results: From 150 patients: 87% males; stage: 90% I-II, 10% III-IV; histology: 42% adenocarcinoma (ADC), 44% squamous (SCC), 14% sarcomatoid carcinoma (SaC). Genomic alterations according to histologic subtype are summarized in Table. PD-L1 was positive in 47% of tumors (49% of ADC, 43% of SCC, 58% of SaC), and correlated with TILs CD8 þ (p <.001) and HLA-1 (p¼.002). PD-L1 positivity was associated with MET alterations (4.5% MET amp, 2% METexon14 skipping), OR ¼ 5.4 (1.4-21.2), p¼.015. ADC harbouring STK11 loss of function were correlated with negative PD-L1 (p ¼ .01) and associated with immunosupressive phenotype (negative PD-L1, low CD8þ), OR ¼ 11.6 (2.1-64), p¼.005. Distinct PD-L1 expression was evidenced in Background: CETCs in the peripheral blood are a prerequisite for the development of metastases. B7-H3 is an important immune checkpoint member of the B7 family and inhibits T-cell mediated anti-tumor immunity. It is highly overexpressed on a wide range of solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Based on the clinical success of the inhibitory immune checkpoint blockade, mAbs against B7-H3 appear to be promising therapeutic strategy. In order to better understand the role of B7-H3 in cancer development we used a noninvasive, real-time biopsy for determining B7-H3 on CETCs in breast cancer patients. Methods: Blood from 50 patients suffering from breast cancer were analyzed for CETCs. The number of vital CETCs and the expression of B7-H3 and Ki-67 were evaluated using the maintracV R method.
Background: PD-L1 expression is associated with clinical benefit from anti-PD1/anti-PD-L1 therapies in advanced NSCLC. However, additional biomarkers are needed to predict which patients will benefit most. The aim of this study is to correlate specific genomic alterations with immunological biomarkers in a cohort of NSCLC. Methods: Patients diagnosed with NSCLC from 2000 to 2005 were retrospectively reviewed. Genetic mutations and copy number of selected genes were determined by Sanger and FISH. Immunophenotype was defined by PD-L1, HLA-1 and TILs CD8þ immunostaining and scored as follows: PD-L1 positivity 5% on membrane tumor cells; HLA-1 intensity: 0þ,1þ,2þ; TILs CD8þ score: low or high infiltration. Statistical analysis using Chi-square test and logistic regression were performed. Results: From 150 patients: 87% males; stage: 90% I-II, 10% III-IV; histology: 42% adenocarcinoma (ADC), 44% squamous (SCC), 14% sarcomatoid carcinoma (SaC). Genomic alterations according to histologic subtype are summarized in Table. PD-L1 was positive in 47% of tumors (49% of ADC, 43% of SCC, 58% of SaC), and correlated with TILs CD8 þ (p <.001) and HLA-1 (p¼.002). PD-L1 positivity was associated with MET alterations (4.5% MET amp, 2% METexon14 skipping), OR ¼ 5.4 (1.4-21.2), p¼.015. ADC harbouring STK11 loss of function were correlated with negative PD-L1 (p ¼ .01) and associated with immunosupressive phenotype (negative PD-L1, low CD8þ), OR ¼ 11.6 (2.1-64), p¼.005. Distinct PD-L1 expression was evidenced in Table: 1647P Genetic alterations according to histologic subtype (N ¼ 150). Background: CETCs in the peripheral blood are a prerequisite for the development of metastases. B7-H3 is an important immune checkpoint member of the B7 family and inhibits T-cell mediated anti-tumor immunity. It is highly overexpressed on a wide range of solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Based on the clinical success of the inhibitory immune checkpoint blockade, mAbs against B7-H3 appear to be promising therapeutic strategy. In order to better understand the role of B7-H3 in cancer development we used a noninvasive, real-time biopsy for determining B7-H3 on CETCs in breast cancer patients. Methods: Blood from 50 patients suffering from breast cancer were analyzed for CETCs. The number of vital CETCs and the expression of B7-H3 and Ki-67 were evaluated using the maintracV R method.
Results: CETCs were detected in all examined patients (ranged from 2-676 CETCs in 100 ml of blood). B7-H3 expression on the surface of CETCs was found in 82% of patients. Triple negative breast cancer patients had statistically significantly more B7- Background: Several groups have reported that programmed death-1 (PD-1) ligand 1 (PD-L1) overexpression on tumor cells predicts a poor prognosis in patients with nonsmall cell lung cancer (NSCLC). Although recent studies have shown that PD-L1 overexpression on tumor cells predicts for improved clinical outcome in NSCLC patients treated with anti-PD-1/PD-L1 immunotherapy, PD-L1 low/negative tumors also benefit from anti-PD-1/PD-L1 immunotherapy. These findings suggest that study on multiple immune parameters should be considered. We recently reported that the overexpression of PD-L1 in tumor predicted a poor prognosis while overexpression of NK cell activating ligand MICA/B predicted improved clinical outcome in patients with resected NSCLC. It is well known that both T cell-and NK cell-mediated tumor recognitions are influenced by HLA class I molecules, however, the roles of HLA class I molecules are different between T cells and NK cells; HLA class I/T cell receptor immune synapse induces antigen-specific cytotoxicity by T cell, while HLA class I/killer cell immunoglobulin-like receptor synapse attenuates NK cell-mediated cytotoxicity. Here, we assessed the multiple immune parameters (PD-L1, MICA/B, and HLA class I) in NSCLC tissues to assess the prognostic factors in patients with resected NSCLC. Background: Human chitinase-like proteins are considered as biomarkers of cancer and chronic inflammation.YKL-39 is a unique member of chitinase-like protein family due to its presence only in humans but not in rodents both on gene and protein levels. However, its biological activity and association with tumor progression remains unknown. Methods: YKL-39 expression and secretion in human monocytes-derived macrophages was measured by RT-PCR and ELISA. Monocyte migration was analyzed in a transwell system. In vitro tube formation assay was performed using HUVEC cells.112 female patients with nonspecific invasive breast cancer of stage IIA-IIIC (T1-4N0-3M0) were included in the study. Confocal microscopy analysis was used to identify cell type expressing YKL-39 in tumor samples.YKL-39 expression level was measured by RT-PCR in tumor biopsy specimens. Results: Human monocytes-derived macrophages differentiated in the presence of IL4 and TGFbeta, but not IL4 alone, were found to express high levels of YKL-39 mRNA and protein. Purified YKL-39 significantly enhanced the migration of human CD14þmonocytes by 1.9 fold (p < 0.01) after 1 h, and 4.9 fold (p < 0.01) after 3 h that was comparable with the effect of MCP-1. In vitro tube formation assays using HUVEC cells demonstrated that YKL-39 has a strong pro-angiogenic effect. In human samples of breast cancer YKL-39 was found to be expressed in CD68þ macrophages but not in cancer cells or other stromal cell types. In breast cancer biopsy specimens it was found that high YKL-39 gene expression correlated with the significantly reduced frequency of lymphatic and hematogenous metastasis. Furthermore, high level of YKL-39 expression associated with 100% metastatic-free survival rate (p ¼ 0.015). Conclusions: TGFbeta is a key cytokine inducing production of YKL-39 in macrophages. YKL-39 stimulates critical for tumor progression processes: chemotaxis of monocytes and angiogenesis. However high levels of YKL-39 expression in tumor samples are predictive for metastatic-free survival in patients with breast cancer, suggesting that YKL-39 can program monocytes and newly growing vessels to inhibit metastatic spread. This study was supported by grant RNF @14-15-00350. Legal entity responsible for the study: Tomsk State University, Tomsk, Russian Federation Funding: Tomsk State University, Tomsk, Russian Federation. This study was supported by grant RNF @14-15-00350. Disclosure: All authors have declared no conflicts of interest. Background: Neutrophil lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are known to be surrogate markers of inflammation and have been shown to predict mortality in patients with heart disease and cancer. In this study, we evaluate the
